

23 June 2026

Type 1 diabetes testing

I am writing under the Freedom of Information Act 2000 to request information held by your organisation regarding Type 1 diabetes testing. Please complete this form with the information you have available.

Q1. Do you provide autoantibody testing for diagnosis of Type 1 diabetes?

Answer:

Q1a. If yes, please indicate which assays are available either onsite or via referral to another laboratory:

- **GAD** – Yes, referred to another laboratory
- **IA-2** – Yes, referred to another laboratory
- **ZnT8** – Yes, referred to another laboratory
- **IAA** - No

Answer:

Q1b. Does your organisation receive requests for Type 1 diabetes autoantibody testing in individuals without clinically diagnosed diabetes (e.g. screening of at-risk relatives or other asymptomatic individuals)?

☐ Yes

☐ No

☒ Unknown

Q1c. Please provide the number of unique patients tested clinically for the following autoantibodies during:

- **Calendar year 2025**
- **January–March 2026**

Please exclude research-only testing where identifiable.

Please provide separate figures for:

- **onsite testing**
- **outsourced/referred testing**

If exact patient numbers are not available, please provide the closest available measure (e.g. request numbers or assay volumes) and specify the metric used.

Answer table: Request numbers provided in table, requests for Diabetes antibodies are all tested for IA2/ZnT8/GAD.

23 June 2026

		Patients Tested Onsite	Outside Lab
2025 (Calendar Year)	GAD only	N/A	N/A
	Combination of any of GAD, IA-2 and/or ZnT8	0	795
	IAA only (if available)	N/A	N/A
1st quarter 2026 (January – March)	GAD only	N/A	N/A
	Combination of any of GAD, IA-2 and/or ZnT8	0	318
	IAA only (if available)	N/A	N/A

Q1d. If an external laboratory is used, please provide:

- **laboratory/provider name**
- **Location**

Answer:

Synnovis
Friars Bridge Court
41-43 Blackfriars Road
London
SE1 8NZ

Q2a. If readily available, please provide the number of unique patients in 2025 and Jan–Mar 2026 who tested positive for:

- i) one autoantibody**
- ii) two or more autoantibodies**

Please exclude research-only testing where possible.

Answer: This information is not readily available.

Q2b. Of the unique patients who tested positive, how many were referred through an early stage/asymptomatic screening programme?

Answer: Unable to answer

Q3. Please provide the average turnaround time over the last 12 months for Type 1 diabetes autoantibody testing:



23 June 2026

- **onsite testing**
- **referred testing (if applicable)**

Answer: Approx 44 days.